Radiotherapy for Lung Cancer
(CURB2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if adding a special type of radiotherapy called SBRT (a precise and intense radiation treatment) can more effectively prevent lung cancer from growing or spreading compared to the usual mix of cancer drugs alone. It targets individuals with non-small cell lung cancer that has metastasized and shown resistance to initial treatments. Ideal participants are those who have experienced limited cancer progression during or after initial treatment with immunotherapy or chemotherapy. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially groundbreaking treatment advancements.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but it mentions that certain drug interactions or overlapping side effects could affect your eligibility. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that SBRT, a type of precise radiation therapy, is generally well-tolerated for treating lung cancer. Studies indicate that SBRT effectively targets and treats cancer in the lungs, with a similar rate of severe side effects as other common radiation therapies.
In everyday practice, most patients receiving SBRT for lung tumors experience manageable side effects. Evidence suggests that short-term side effects and the risk of death within 90 days remain within safe limits for patients with early-stage non-small cell lung cancer (NSCLC). This suggests that SBRT is a relatively safe option compared to other treatments.
Overall, SBRT appears to be a safe choice, providing effective results with side effects that most patients can tolerate.12345Why do researchers think this study treatment might be promising for lung cancer?
Researchers are excited about the use of Stereotactic Body Radiotherapy (SBRT) for lung cancer because it offers a more precise and intense form of radiotherapy compared to traditional methods. Unlike standard treatments that often require numerous sessions, SBRT delivers high doses of radiation in fewer treatments, potentially reducing the overall treatment time and improving patient convenience. Additionally, SBRT's precision minimizes damage to surrounding healthy tissue, which could lead to fewer side effects. This approach is especially promising for targeting small, well-defined tumors, offering hope for improved outcomes in lung cancer care.
What evidence suggests that SBRT might be an effective treatment for lung cancer?
Research has shown that Stereotactic Body Radiotherapy (SBRT) effectively controls lung tumors. For example, one study found that SBRT successfully controlled 96.7% of tumors after one year and 77.8% after five years. This indicates that SBRT can stop tumors from growing or spreading for many patients. Another study demonstrated that SBRT worked well in real-world settings, providing good control of lung tumors with manageable side effects. In this trial, one group of participants will receive SBRT followed by standard care therapy, while another group will switch to second-line standard care therapy without SBRT. These findings suggest that adding SBRT to standard lung cancer treatments could improve patient outcomes by better controlling tumor growth.36789
Who Is on the Research Team?
C. Jillian Tsai
Principal Investigator
University Health Network Princess Margaret Hospital, Toronto, ON Canada
Are You a Good Fit for This Trial?
This trial is for adults with stage IV non-small cell lung cancer without actionable mutations, who've had at least 3 cycles of first-line therapy. They should have stable brain metastases if present, be able to undergo SBRT safely, and fit enough (ECOG status 0-2) to receive second-line standard care.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiotherapy
Participants receive targeted radiotherapy to block oligoprogression
Standard of Care Therapy
Participants receive standard of care therapy following radiotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- SBRT
Trial Overview
The study tests whether adding targeted radiotherapy (SBRT) to the usual drug combination can better control lung cancer growth or spread compared to standard treatment alone. Participants will either continue with their current treatment or get the added radiotherapy.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Find a Clinic Near You
Who Is Running the Clinical Trial?
Canadian Cancer Trials Group
Lead Sponsor
NRG Oncology
Collaborator
SWOG Cancer Research Network
Collaborator
Alliance for Clinical Trials in Oncology
Collaborator
ECOG-ACRIN Cancer Research Group
Collaborator
Citations
Stereotactic body radiotherapy in lung cancer - PubMed Central
SBRT-related death occurred in 6 patients after 0.6–19.5 months after treatment [33]. The 4-year results of the study were published by Fakiris ...
A prospective outcomes and cost-effective analysis of surgery ...
It was designed to compare multidisciplinary treatment selection and outcomes of SBRT to surgery using prospective data on patient satisfaction, ...
121 - stereotactic body radiation therapy for octogenarians ...
SBRT demonstrated high efficacy in local tumour control, with a 1-year LC rate of 96.7% and a 5-year LC rate of 77.8%. The mean LC was 4.99 years, suggesting ...
Real-World Evidence of Health Outcomes Related to Lung ...
Our results indicate that SBRT is effective (high local control and acceptable toxicity) for treating malignant lung lesions in a real-world scenario in Latin ...
Four-year follow-up outcomes after stereotactic body radiation ...
Conclusions: SBRT with a BED 100 Gy in 4–10 fractions is effective and acceptable for treating patients with central early-stage NSCLC. Further studies are ...
Long-term Clinical Outcomes and Safety Profile of SBRT for ...
SBRT for central lung tumors offers very high rates of LC and acceptable rates of severe toxicity comparable with peripheral tumors.
Real-World Acute Toxicity and 90-Day Mortality in Patients ...
This study aimed to uncover the real-world incidence of acute toxicity and 90-day mortality in patients with SBRT-treated stage I NSCLC and ...
Safety and Efficacy of Stereotactic Body Radiation Therapy ...
A total of 154 patients received SBRT to 162 ultracentral lesions during our study period, with baseline characteristics described in Table 1.
9.
por-journal.com
por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2024.1611709/fullStereotactic body radiotherapy in lung cancer
Both in terms of 3-year estimated OS (SBRT: 95%, lobectomy: 79%) and recurrence-free survival (SBRT: 86%, lobectomy: 80%), patients who received ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.